NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Given Average Recommendation of “Hold” by Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has received a consensus recommendation of “Hold” from the five research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $7.3333.

Several equities analysts recently issued reports on NMTC shares. Weiss Ratings cut NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Maxim Group set a $5.00 price target on shares of NeuroOne Medical Technologies and gave the company a “buy” rating in a report on Friday, August 14th.

NeuroOne Medical Technologies Stock Performance

Shares of NeuroOne Medical Technologies stock opened at $1.36 on Friday. The firm has a market cap of $12.39 million, a PE ratio of -1.43 and a beta of 0.65. NeuroOne Medical Technologies has a 1 year low of $1.35 and a 1 year high of $6.96. The firm’s 50-day simple moving average is $1.85 and its 200-day simple moving average is $3.29.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Thursday, August 13th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). The firm had revenue of $1.97 million for the quarter, compared to the consensus estimate of $2.17 million. NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%. On average, equities analysts predict that NeuroOne Medical Technologies will post -0.39 earnings per share for the current year.

Insider Transactions at NeuroOne Medical Technologies

In other NeuroOne Medical Technologies news, Director Mark Christianson sold 10,000 shares of NeuroOne Medical Technologies stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total value of $31,800.00. Following the completion of the transaction, the director directly owned 20,692 shares in the company, valued at $65,800.56. The trade was a 32.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David J. Wambeke bought 33,333 shares of the stock in a transaction dated Thursday, August 27th. The shares were bought at an average cost of $2.01 per share, with a total value of $66,999.33. Following the completion of the acquisition, the insider directly owned 199,999 shares of the company’s stock, valued at approximately $401,997.99. The trade was a 20.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 11.80% of the company’s stock.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Several large investors have recently added to or reduced their stakes in the stock. Bard Associates Inc. acquired a new position in shares of NeuroOne Medical Technologies during the second quarter valued at $929,000. BlackRock Inc. bought a new position in shares of NeuroOne Medical Technologies during the second quarter worth about $76,000. Susquehanna International Group LLP acquired a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter worth about $41,000. Finally, Legato Capital Management LLC acquired a new stake in shares of NeuroOne Medical Technologies in the 4th quarter worth about $34,000. 16.07% of the stock is owned by institutional investors and hedge funds.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.